

Kevin J. Scanlon, Ph.D.
November, 2018

Dr. Scanlon's background includes: academic medicine, senior manager in the pharmaceutical industry and the investment community. Dr. Scanlon was identified by "LA Techweek" in 2013 as an individual impacting the Los Angeles business and the technology landscape on a significant scale.

Education:

Yale School of Medicine, New Haven, CT
Post Doctoral Fellow, Pharmacology Department

University of London, Royal Holloway College,
London, England
Graduate Student (Ph.D.), Biochemistry Department

Sacred Heart University, Fairfield, CT
(B.A.) Biology-Chemistry (major) Philosophy (minor)

Currently Position:

Professor of Practice (2015- present)

Center for Entrepreneurship & Innovation at
D'Amore-McKim School of Business
Northeastern University, Boston, MA.

INVESTMENT EXPERIENCE:

Sky Ventures; Investment Advisor (2015- present)

Sky Ventures is powering the future of health care and life science ecosystem by bringing together a wide network of startup founders, investors and industry leaders. The member meetings are held at Northeastern University.

**Pasadena Angels; Emeritus Chairman (2014-2015), Chairman (2012-2014)
Vice-Chairman (2011), Director (2004-2014)**

The Pasadena Angels provides a forum for companies to develop their business and financing plans. We have about 100 SEC accredited investors (~20 woman) that have funded over 50 companies (~\$9MM) in 2 years. Dr. Scanlon has syndicated deals with several other local, regional Dr. Scanlon managed the funding of Wasatch Microfluidics (Salt Lake City, UT) in 30 days for \$475,000. We have consistently ranked in the top ten angel groups in the United States.

Tech Coast Angels (TCA); Executive Member (2004-2014)

Dr. Scanlon was an advisor to the tech transfer offices at UCLA, USC Stevens and Cal Tech. He helped evaluate university technology opportunities for the angel investors. We have invested over \$200 million in more than 300 companies, with follow on funding over \$1.5 Billion since 1998. TCA is the largest angel group and is consistently ranked in the top ten angel groups in the United States.

PROFESSIONAL EXPERIENCE:

International BioScience, Boston, MA.; CEO and Founder (2004-Present)

Dr. Scanlon role is to be bridge the worlds of academia, industry and venture community. He has provided these services in Ireland helping fund the National Institute of Cellular Biotechnology, the Treasury Department of the Government New Zealand and the governments in Shenyang and Shenzhen, China. His articles on entrepreneurship can be found on his website (www.kjscanlon.com).

Makucell, Altadena, CA; CEO and Chairman (2013-2014) Board Advisor (2012-2013)

This company was founded on technology from the University of Southern California, School of Medicine. The company had a proprietary small molecule that can stimulate stem cells in the skin. These molecules have been incorporated into skin products to stimulate skin cell growth. The product was validated in an independent study with 40 subjects. The local angel groups funded this company.

Melanoma Diagnostics, Altadena, CA CEO and Chairman (2006-2011)

This medical technology was licensed from the University of California at San Francisco. The company commercialized a diagnostic assay for discriminating moles from melanoma and a multi-marker prognostic assay. Dr. Scanlon sold the company to Myriad Genetics in December 2010. This assay is currently going to market for screening patients for melanoma.

LA County Business Technology Center, Altadena, CA Board Advisor (2004-2014)

The BTC is owned and operated by the County of Los Angeles Community Development Commission. The BTC was opened (1998) with ~30 technology companies drawn from the local universities and JPL in Pasadena. The Pasadena Angels have their offices in the building and mentor the companies.

Berlex/Schering, Berlin, Germany Vice President, Cancer Division (1995-2000)

Dr. Scanlon had responsibility for developing genomics and gene therapy program through internal company collaborations between Berlin, Germany, Osaka, Japan and several biotechnology companies. Novel cancer genes were identified and validated for their role as drug targets in the pathogenesis of cancer. These genes have been identified for therapeutic or diagnostic agents with filed patents. A cancer diagnostic product was taken from concept to clinical validation in 18 months. This program involved genomics, diagnostics, small molecules and gene therapy projects. He successfully manages a staff of over 150 internal and external employees and a budget of over \$50 MM/ annum.

Teaching:**UCLA, School of Management, Los Angeles, CA; Faculty (2006-2014)**

The Global Access Program is a unique six-month program for the Fully-Employed MBA students. The program develops a comprehensive business strategy for an international company to enter the US market. The student plans are based on extensive primary and secondary research. Dr. Scanlon has four teams (five students in each team) to advise them in their field studies with life science companies. The course focuses on business management and entrepreneurship. The course requires Dr. Scanlon to advise the teams on their business plan (45 pages) and a 20-minute presentation to a panel of expert judges in the field.

**California Institute of Technology, Pasadena, CA
Entrepreneurial Program, Mentor (2006-2014)**

This 10-week Entrepreneurial Development Course is designed for Caltech students who are interested in starting up high tech companies early in their careers. Dr. Scanlon advises a team on their 10-page business plan and a 20-minute presentation to judges.

Keck Graduate Institute Claremont, CA; Professor (2000-2004)

Dr. Scanlon was responsible for the development of the Pharmaceutical Development graduate courses. He was the faculty coordinator for the summer internship program and the team masters research program sponsored by the Bio-Pharmaceutical Industry. He was also the Principal Investigator of a \$600,000 federally funded grant entitled "Partnerships for Innovation" to support the development of entrepreneur businesses with the Bioscience Community.

ISSUED PATENTS from 1991-1999 (Patent #)

(5,085,983) Detection of Tumor Progression and Drug Resistance

(5,166,140) Nucleotide Analogs Attenuate DNA Damaging Agents

(5,508,558) A Method Regulating Drug & Radiation Resistance Genes

(5,585,363) Circumvention of Human Tumor Drug Resistance

(5,618,702) PCR Amplification of m-RNA

(5,880,277) Ribozyme Cleavage of 5a-Reductase MRNA

(5,989,908) Modulation of Drug and Radiation Resistant Genes

EDITOR:

1993 Co-Founder & Co-Editor, *Cancer Gene Therapy*, Emeritus Editor (2014)

1998: Editor, *Human Gene Therapy*, Schering Res. Found, #28 (Springer)

1998: Co-Editor, *Ribozymes in Cancer Medicine*, Medical Intel. (Landes)

1998: Editor, *Therapeutic Applications of Ribozymes*, Mol. Medicine

1995: Co-Editor, *Internet Book on Gene Therapy, Cancer Therapeutics*

MEMBERSHIPS – PROFESSIONAL ORGANIZATIONS

1992 -- 2004 Co-Founder, Cancer Gene Therapy Conference, San Diego, California
1984 – 2004 American Association for Cancer Research
1997 – 2004 American Society of Gene Therapy
1998 – 2004 International Society of Cancer Gene Therapy; Council Member & President
1989 – 1994 National Institutes of Health – Physiological Sciences Study Section
1994 – 1998 National Institutes of Health – Clinical Cancer Study Section D
1998 – 2000 California Breast Cancer Research Program; Council Member
2004 -- 2005 National Institute of Health – Cancer Biomarkers Study Section

BOARDS:

International:

2009-2013: Molecular Therapeutics for Cancer Ireland, Dublin, Ireland
2009-2012: Community First Initiative, Siem Reap, Cambodia
2007-2014: Dublin City University, Dublin, Ireland
2000-2014: National Institute Cellular Biotechnology, Dublin, Ireland

National:

2007-2013: Numira Bioscience, Irvine, CA
2006-2013: Pivotal Bioscience, Los Angeles, CA.
2004-2014: Los Angeles Business Technology Center, Altadena, CA

SELECTED PUBLICATIONS (total: 137 papers)

Scanlon K.J., Newman, E.M., Lu Y., and Priest D.G. Biochemical basis for cisplatin and 5-Fura synergism in human ovarian carcinoma cells. **Proc. Nat'l. Acad. Sci. (USA) 83:8923-8925, 1986.**

Scanlon, K.J. and Kashani-Sabet, M. Elevated expression of dTMP synthase cycle genes in cisplatin-resistant human ovarian carcinoma cells. **Proc. Nat'l. Acad. Sci (USA) 85:650-653, 1988.**

Lu, Y., Han, J., and **Scanlon, K.J.** Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. **J. Biol. Chem. 263:4891-4894, 1988.**

Kashani-Sabet, M., Rossi, J.J., Lu, Y., Ma, J.X., Chen, J., Miyachi, H., and **Scanlon, K.J.** Detection of drug resistance in human tumors by PCR assay. **Cancer Research 48:5775-5778, 1988.**

Kashani-Sabet, M., Wang, W., and **Scanlon, K.J.** Cyclosporin A suppresses cisplatin-induced *c-fos* gene expression in ovarian carcinoma cells. **J. Biol. Chem. 263:11285-11288, 1990.**

Scanlon, K.J., Jiao, L., Funato, T., Wang, W., Tone, T., Rossi, J.J., and Kashani-Sabet, M. Ribozyme-mediated cleavage of *c-fos* mRNA reduces gene

expression of DNA synthesis enzymes and metallothionein. **Proc. Nat'l. Acad. Sci. (USA) 88:10592-10595, 1991.**

Kashani-Sabet, M., Funato, T., Tone, T., Jiao, L., Wang, W., Yoshida, E. Wu, A.M., and **Scanlon, K.J.** Reversal of the malignant phenotype by an anti-*ras* ribozymes. **Antisense Res. & Dev., 2:3-15, 1992.**

Kashani-Sabet, M., Funato, T., Florenes, V.A., Fodstad, O., and **Scanlon, K.J.** Suppression of the neoplastic phenotype *in vivo* by an anti-*ras* ribozyme. **Cancer Research 54:900-902, 1994.**

Scanlon, K.J., Ishida, H., and Kashani-Sabet, M. Reversal of the multi-drug resistant phenotype by a *fos* ribozyme. **Proc. Nat'l. Acad. Sci. (USA) 91:11123-11127, 1994.**

Feng, M., Cabrera, G., **Scanlon, K.J.,** and Curiel, D. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-*ras* ribozyme. **Cancer Research 55:2024-228, 1995.**

Ohta, Y., Kijima, H., Ohkawa, T., Kashani-Sabet, M., and **Scanlon, K.J.** Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. **J. Invest. Derm. 106:275-280, 1996.**

Tsuchida., T., Kijima, H., Hori, S., Oshika, Y., Tokunaga, T., Kawai, K., Yamazaki, H., Y., **Scanlon, K.J.,** Tamaoki, N., and Nakamura, Adenovirus-mediated anti-Kras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. **Gene Therapy, 7:373-383, 2000.**

INVITED PAPERS

Scanlon, K.J. and Kashani-Sabet, M. Ribozymes and Antisense. **Encyclopedia of the Human Genome**, Nature Publishing Group, Article #762, 2002.

Scanlon, K. J. Cancer Gene Therapy: Challenges and Opportunities. *Anticancer Res.*, 24: 501-4, 2004

Scanlon, K. J. Anti-Genes: siRNA, Ribozymes & Antisense. *Curr. Pharma. Biotechnology*, 5:415-420, 2004.

Contact Information:

Dr. Kevin J. Scanlon

Dodge Hall, Room #152E

Boston, MA 02123

626-688-6544 (cell phone)

k.scanlon@neu.edu

www.linkedin.com/in/kjscanlon/en

www.kjscanlon.com